StockData
Emmaus Life Sciences, Inc. logo

Emmaus Life Sciences, Inc. (EMMA) stock

EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.05−0.01 (-14.38%)

Close on Oct 19, 2026Market cap $6.03MP/E –Yield –

Emmaus Life Sciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Emmaus Life Sciences's operating income for the twelve months ending Jun 30, 2026 was $4.55M. For fiscal 2025 it was $231.00K. The highest annual figure on record is $3.54M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$231.00K–
FY2024Dec 31, 2024-$1.89M-153.5%
FY2023Dec 31, 2023$3.54M–
FY2022Dec 31, 2022-$6.59M–
FY2021Dec 31, 2021-$6.13M–
FY2020Dec 31, 2020-$32.00K–
FY2019Dec 31, 2019-$4.51M–
FY2017Sep 30, 2017-$7.10M–
FY2016Sep 30, 2016-$3.77M–
FY2015Sep 30, 2015-$2.65M–
FY2014Sep 30, 2014-$3.82M–
FY2013Sep 30, 2013-$4.20M–
FY2012Sep 30, 2012-$4.81M–
FY2011Sep 30, 2011-$5.29M–
FY2010Sep 30, 2010-$6.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$3.79M–
Q1 FY2026CQ1 2026Mar 31, 2026-$823.00K-200.2%
Q4 FY2025CQ4 2025Dec 31, 2025$886.00K+52.2%
Q3 FY2025CQ3 2025Sep 30, 2025$695.00K–
Q4 FY2024CQ4 2024Dec 31, 2024-$557.00K-141.1%
Q3 FY2024CQ3 2024Sep 30, 2024$821.00K+3320.8%
Q2 FY2024CQ2 2024Jun 30, 2024$582.00K-82.5%
Q1 FY2024CQ1 2024Mar 31, 2024-$2.74M–
Q4 FY2023CQ4 2023Dec 31, 2023$1.36M–
Q3 FY2023CQ3 2023Sep 30, 2023$24.00K–
Q2 FY2023CQ2 2023Jun 30, 2023$3.33M–
Q1 FY2023CQ1 2023Mar 31, 2023-$1.17M–
Q4 FY2022CQ4 2022Dec 31, 2022-$1.42M–
Q3 FY2022CQ3 2022Sep 30, 2022-$660.00K–
Q2 FY2022CQ2 2022Jun 30, 2022-$1.44M-398.1%
Q1 FY2022CQ1 2022Mar 31, 2022-$3.07M–
Q4 FY2021CQ4 2021Dec 31, 2021-$4.97M-1475.3%
Q3 FY2021CQ3 2021Sep 30, 2021-$31.00K-487.5%
Q2 FY2021CQ2 2021Jun 30, 2021$483.00K–
Q1 FY2021CQ1 2021Mar 31, 2021-$1.62M-242.4%
Q4 FY2020CQ4 2020Dec 31, 2020$361.00K–
Q3 FY2020CQ3 2020Sep 30, 2020$8.00K-93.1%
Q2 FY2020CQ2 2020Jun 30, 2020-$1.54M–
Q1 FY2020CQ1 2020Mar 31, 2020$1.13M–
Q4 FY2019CQ4 2019Dec 31, 2019-$3.35M–
Q3 FY2019CQ3 2018Jun 30, 2019$116.00K–
Q4 FY2017CQ3 2017Sep 30, 2017-$2.69M–
Q3 FY2017CQ2 2017Jun 30, 2017-$1.55M–
Q2 FY2017CQ1 2017Mar 31, 2017-$1.42M–
Q1 FY2017CQ4 2016Dec 31, 2016-$1.44M–
Q4 FY2016CQ3 2016Sep 30, 2016-$1.64M–
Q3 FY2016CQ2 2016Jun 30, 2016-$809.20K–
Q2 FY2016CQ1 2016Mar 31, 2016-$690.00K–
Q1 FY2016CQ4 2015Dec 31, 2015-$624.70K–
Q4 FY2015CQ3 2015Sep 30, 2015-$533.60K–
Q3 FY2015CQ2 2015Jun 30, 2015-$556.00K–
Q2 FY2015CQ1 2015Mar 31, 2015-$780.10K–
Q1 FY2015CQ4 2014Dec 31, 2014-$779.20K–

More Emmaus Life Sciences figures

See a number that looks wrong?